Last reviewed · How we verify
Rifampicin and levofloxacin
Rifampicin and levofloxacin is a Small molecule drug developed by Leiden University Medical Center. It is currently FDA-approved.
Rifampicin and levofloxacin, marketed by Leiden University Medical Center, is a combination therapy with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and dual-action mechanism. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Rifampicin and levofloxacin |
|---|---|
| Sponsor | Leiden University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus (PHASE3)
- Shorter and Safer Treatment Regimens for Latent TB (PHASE2, PHASE3)
- Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women (PHASE1)
- A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets (PHASE2)
- Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2) (PHASE3)
- STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifampicin and levofloxacin CI brief — competitive landscape report
- Rifampicin and levofloxacin updates RSS · CI watch RSS
- Leiden University Medical Center portfolio CI